Optimal Balance Alfapump® System Feasibility Study (OPTIMALBALANCE)

A Feasibility Clinical Study of Osmotic Pump Treatment in Fluid Management to Achieve Optimal Fluid Balance in NYHA Class III and Ambulatory NYHA Class IV Heart Failure Patients Who Have an Estimated Glomerular Filtration Rate of > 15 to < 60 mL/Min/1.73m2

1. Summary of Clinical Investigation

A summary of the clinical investigation is provided below and includes the primary objective of the study, the safety and feasibility endpoints, the number of subjects to be enrolled, the study duration, the subject follow-up and the inclusion/exclusion criteria.

1. Primary Objective

   The primary objective of the study is to evaluate the safety and feasibility of the alfapump® System indication for use in the management of fluid in NYHA Class III and ambulatory NYHA Class IV heart failure patients who have an eGFR of > 15 to < 60 mL/min/1.73m2.

2. Study Endpoints

   1. Primary Safety Endpoint

      The primary safety endpoint will be an assessment of the occurrence of adverse events (AEs) and serious adverse events (SAEs) related to:

      1. Surgical implant of the alfapump®
      2. Device malfunctions
      3. Dialysate infusion

   2. Secondary Safety Endpoints

      The secondary endpoint will be an assessment of:

      1. Time to first hospitalization related to fluid management after the activation of the alfapump® System and initiation of dialysate infusion has occurred
      2. Rate of occurrence of re-hospitalizations related to fluid management
      3. All-cause mortality
   3. Assessment of Feasibility for Fluid Management in Heart Failure Indication The feasibility of the alfapump® System for management of fluid in NYHA Class III and ambulatory NYHA Class IV heart failure patients with renal dysfunction will be assessed by the net fluid balance as measured by the ability of the alfapump® System to move more fluid to the bladder than dialysate instilled.

Study Overview

• Status: Withdrawn
• Conditions: Heart Failure
• Intervention / Treatment: Device: Alfapump

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

Study Locations

• Hungary
  • Budapest, Hungary, 1134
    • Military Hospital - State Health Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

• Males or females ≥ 18 years and < 80 years of age
• Patients exhibiting physical signs of excessive fluid retention (i.e. elevated JVD, peripheral edema, ascites, pulmonary edema, weight gain etc.)
• Patients with an eGFR by the Modification of Diet in Renal Disease (MDRD) of > 15 to < 60 mL/min/1.73m2
• Patients with a brain natriuretic peptide (BNP) ≥ 150 pg/mL and/or N-terminal prohormone of brain natriuretic peptide (NT-proBNP) ≥ 600 pg/mL at time of screening or BNP ≥ 100 pg/mL and/or NTproBNP ≥ 400 pg/mL
• Patients who have a Six Minute Walk Test (SMWT) exercise capacity between 100 and 400 meters

• Patients presenting with NYHA Class III or ambulatory NYHA Class IV heart failure who have been on optimal medical management (OMM) based on current heart failure practice guidelines and who are failing to respond to or cannot tolerate one or more of the following interventions:

  1. Treatment with diuretic therapy
  2. Treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for at least 30 days
  3. Treatment with nitrates and/or vasodilators at the investigator's discretion
  4. Treatment with beta-blockers for at least 90 days
  5. Treatment with cardiac resynchronization therapy (CRT)
  6. Treatment with an automatic implantable cardioverter defibrillator (AICD)
• Patients who demonstrate compliance with the current medical regimen as reported by the treating physician

Enrollment Exclusion Criteria

• Patients presenting with acute decompensated heart failure requiring hospitalization for management of their symptoms (i.e. hospitalization for exacerbation of chronic heart failure manifested by signs and symptoms requiring intravenous and/or more aggressive therapy)
• Patients with ascites on physical examination resulting predominantly from right heart failure
• Patients who have an indication for and are candidates for CRT but who have not been treated with CRT
• Patients who have an indication for and are candidates for an AICD but who have not been implanted with an AICD
• Patients with reversible causes of heart failure which may be remedied by conventional surgery or other interventions
• Patients with an eGFR by MDRD < 15 or > 60 ml/min/1.73m2
• Patients with a body mass index (BMI) < 18 kg/m2or > 35 kg/m2
• Patients with severe pulmonary disease by history (i.e. severe chronic obstructive pulmonary disease, severe hypoxia or a pulmonary artery mean pressure >40 mm Hg)
• Patients who have experienced a myocardial infarction (MI) within the past 90 days
• Patients who have experienced a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 90 days
• Patients who have undergone cardiac surgery or other major surgery within the past 90 days
• Patients who are candidates for and require a concomitant surgical procedure [i.e. coronary artery bypass graft (CABG), valvular surgery, etc.
• Patients who are candidates for and require temporary or durable mechanical circulatory support [i.e. intra-aortic balloon pump (IABP), ventricular assist device (VAD), extracorporeal membrane oxygenation (ECMO)]
• Patients with confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter diagnosed within the past six months
• Patients with active systemic or uncontrolled infections
• Patients who are pregnant (Note: Negative pregnancy test will be required in all women - Patients with known alcohol or illicit drug abuse or dependence within the previous three months
• Patients who are currently enrolled or who have participated in the past 30 days in another therapeutic and/or interventional clinical study
• Patients with technical obstacles that pose an inordinately high surgical risk in the judgment of the Investigator
• Patients who have any underlying condition that, in the opinion of the Investigator, would disqualify the patient for inclusion in the study, limit survival to less than one year, or not permit valid consideration

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment; Alfapump	Device: Alfapump; Implant Alfapump® System

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of adverse events (AEs) and serious adverse events (SAEs)	4 weeks after the third patient implanted an initial safety review will be done and after the last patient completed 3 months of dialysate administration.	Q1 2017 and Q3 2017

Collaborators and Investigators

• Sponsor: Sequana Medical N.V.

Study record dates

Study Major Dates

• Study Start (Anticipated): December 31, 2017
• Primary Completion (Anticipated): December 31, 2020
• Study Completion (Anticipated): December 31, 2020

Study Registration Dates

• First Submitted: August 11, 2016
• First Submitted That Met QC Criteria: January 23, 2017
• First Posted (Estimate): January 26, 2017

Study Record Updates

• Last Update Posted (Actual): March 22, 2021
• Last Update Submitted That Met QC Criteria: March 18, 2021
• Last Verified: April 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure
• Other Study ID Numbers: 2016-CHF-003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Study cancelled, therefore not applicable at time of answering this remark.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No